Stanford University
Showing 21-40 of 47 Results
-
Abby C. King
David and Susan Heckerman Professor and Professor of Epidemiology & Population Health and of Medicine (Stanford Prevention Research Center)
Current Research and Scholarly InterestsMy interests include applications of behavioral theory and social ecological approaches to achieve large scale changes impacting chronic disease prevention and control; expanding the reach and translation of evidence-based interventions through state-of-the-art technologies; exploring social and physical environmental influences on health; applying community participatory research perspectives to address health disparities; and policy-level approaches to health promotion/disease prevention.
-
Allison W. Kurian, M.D., M.Sc.
Professor of Medicine (Oncology) and of Epidemiology and Population Health
Current Research and Scholarly InterestsI aim to understand cancer burden and improve treatment quality at the population level. I have a strong focus on genetic risk assessment and precision oncology. I lead epidemiologic studies of cancer risk factors, clinical trials of novel approaches to cancer risk reduction, and decision analyses of strategies to optimize cancer outcomes.
-
Uri Ladabaum
Professor of Medicine (Gastroenterology and Hepatology)
Current Research and Scholarly InterestsGastrointestinal cancer prevention and risk management. Risk stratification. Cost-effectiveness analysis. Health services research.
-
Marvin Langston
Assistant Professor of Epidemiology and Population Health and, by courtesy, of Urology
BioDr. Marvin Langston is an Assistant Professor of Epidemiology and Population Health. He is a member of the Stanford Cancer Institute and Urologic Cancer Epidemiology Lab. He is an epidemiologist by training who focuses on the fields of benign prostate and pelvic conditions and urological cancers including prostate and kidney cancers.
Prior to Stanford, he served as a Research Scientist in the Division of Research at Kaiser Permanente Northern California. Dr. Langston received his PhD in Epidemiology from the University of Arizona’s College of Public Health followed by postdoctoral training in Cancer Prevention and Control at Washington University in Saint Louis School of Medicine.
His program of research intends to characterize and measure infectious agents, environmental toxicants, and lifestyle factors; to evaluate the role of these factors in urological cancer etiology and outcomes; and to identify populations at high risk of exposure to these factors. So far he has focused this research to address the following questions: 1) What role do sexually transmitted infections and other systemic infections have in prostate damage and ensuing prostate cancer risk? 2) How can we appropriately model and define early life risk factors for urological cancers? 3) Can we harmonize molecular and clinical aspects of urological condition diagnoses to produce well characterized outcomes for biomarker discovery and etiological investigation? He has primarily addressed these questions using a variety of molecular and clinical epidemiology approaches while developing expertise in the cross-cutting theme of cancer health disparities with particular interests in the cancer care experiences of sexual and gender minorities and racial/ethnic minorities.
Dr. Langston has been studying the impact of exogenous factors on prostate specific antigen (PSA) concentration in young men as a marker of prostate damage and inflammation for over a decade. As early life PSA has been found predictive of future prostate cancer mortality, he has now setout to optimize risk-stratified screening for prostate cancer. This promising approach uses men’s baseline PSA values to inform their risk of future aggressive and/or fatal prostate cancer and determine their frequency of further screening. Under this approach, men with high baseline age-specific total PSA levels receive more frequent screening and men with lower levels receive less frequent screening. Dr. Langston was awarded an R01 from NCI to evaluate this approach using historically collected biospecimen. His funded research trajectory to this point also includes four training awards (2-NCI and 2-NIDDK) and several internal grants. Dr. Langston was selected in the inaugural class of the White House Cancer Moonshot Scholars for his work. -
Jennifer Lee
Professor of Medicine (Endocrinology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsI am a healthcare lead and physician scientist for innovation, R&D, and advanced analytics, and oversee these aspects at VA Palo Alto/VHA, within Stanford-VA relationship. The VA has the US's largest health care system and longest running EHR. I prioritize enabling multiple partners (industry, government, academia, foundations), to innovate/R&D in the VA health care system. We prioritize mentoring students from various Schools to become future leaders in R&D, innovation, and healthcare.
-
Eleni Linos, MD, MPH, DrPH
Ben Davenport and Lucy Zhang Professor of Medicine, Professor, of Medicine (Center for Digital Health) and, by courtesy, of Epidemiology and Population Health
BioEleni Linos MD, MPH, DrPH, is the Director of the Stanford Center for Digital Health. She is a Professor of Dermatology and Epidemiology at Stanford University. Dr. Linos also serves as an Associate Dean for Research at Stanford Medicine, leading the training and mentoring of the next generation of translational research scientists.
Dr. Linos' research focuses on the use of technology in health, dermatology, public health, cancer prevention and the care of older adults. She is dually trained in epidemiology and dermatology and is the principal investigator of several NIH funded studies aimed at improving the lives of patients worldwide. She received her undergraduate degree from Trinity College, Cambridge and medical degree from Christ Church College, Oxford University in the UK. She then received a master’s and doctoral degree from the Harvard School of Public Health and completed her residency in Dermatology at Stanford University.
Linos has been continuously funded by the NIH since 2016, as principal investigator of several studies on technology, aging and dermatology. Her scholarly output includes over 200 peer-reviewed publications, an h-index of 51, and more than 10,000 citations across disciplines. Linos was awarded the NIH Director’s New Innovator Award and received the Paul Beeson Emerging Leaders Award in Aging.
As the Director of the Stanford Center for Digital Health, she has built and led infrastructure bringing together scientists and industry leaders across all Stanford schools to catalyze research across the fields of medicine, computer science, engineering, robotics, policy and public health.
Dr. Linos is committed to mentorship and training of the next generation of scientists in translational research. She has personally mentored over 60 physician-scientists, many of whom are now independently-funded investigators and leaders in academic medicine. She also serves as the co-PI of Stanford CTSA’s K12 Program, responsible for mentorship and training of 10 translational science faculty each year. Over the last seven years, she is funded by an NIH K24 mentorship grant award to mentor the next generation of physician-scientists in dermatology. In addition, Linos is committed to mentorship and supporting students across all levels of education to pursue their passions including students in high school and undergraduates.
Clinically, Dr. Linos is a Board Certified Dermatologist and cares for patients with skin disease in the Stanford Dermatology teaching clinics. -
Karl Lorenz
Professor of Medicine (Primary Care and Population Health)
BioDr. Karl Lorenz, MD MSHS is a general internal medicine and palliative care physician, and Section chief of the VA Palo Alto-Stanford Palliative Care Program. Formerly at the VA Greater Los Angeles, Dr. Lorenz directed palliative care research at the VA Center for Innovation to Implementation and served on the faculty at the UCLA School of Medicine. Dr. Lorenz is a member of the VA’s national Hospice and Palliative Care Program (HPC) leadership team, director of the operational palliative care Quality Improvement Resource Center (QuIRC), and adjunct facility staff member at RAND. Dr. Lorenz’s work and leadership has been influential to the field of palliative care research. Under Dr. Lorenz’s leadership, since 2009 the Quality Improvement Resource Center (QuIRC) has served as one of three national leadership Centers responsible for strategic and operational support of the VA’s national hospice and palliative care programs. QuIRC develops and implements provider facing electronic tools for the VA’s national electronic medical record to improve the quality of palliative care. In that role, Dr. Lorenz participates with the national leadership team in strategic planning, policy development, and providing resources to support operational efforts. Dr. Lorenz has contributed to the field of global palliative care, serving the World Health Organization in its development of Palliative Care for Older People and leading methods for Palliative Care Essential Medications.
-
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsWe conduct clinical trials and epidemiological, translational, and real-world studies of liver cancer, fatty liver (NASH, NAFLD), viral hepatitis B and C, liver cirrhosis, and liver transplant. We focus on risk identification for disease prevention and treatment for improvement of survival. We focus on sex, racial/ethnic, and socioeconomic disparities. We specialize in clinical trials, large international real-world consortium registry data, and large public/semi-public databases.
-
Doug Owens
Henry J. Kaiser, Jr. Professor, Senior Fellow at the Freeman Spogli Institute for International Studies and Professor, by courtesy, of Management Science and Engineering
Current Research and Scholarly InterestsMy research uses decision modeling, cost-effectiveness analysis, and meta-analysis to evaluate clinical and health policy problems. Much of my work involves development of national guidelines for prevention and treatment.
-
VJ Periyakoil, Professor of Medicine
Professor of Medicine (Primary Care and Population Health)
Current Research and Scholarly InterestsMy lab is focused on longevity and healthy aging research.
-
Sylvia K. Plevritis, PhD
William M. Hume Professor in the School of Medicine, Professor of Biomedical Data Science and of Radiology
Current Research and Scholarly InterestsMy research program focuses on computational modeling of cancer biology and cancer outcomes. My laboratory develops stochastic models of the natural history of cancer based on clinical research data. We estimate population-level outcomes under differing screening and treatment interventions. We also analyze genomic and proteomic cancer data in order to identify molecular networks that are perturbed in cancer initiation and progression and relate these perturbations to patient outcomes.
-
Judith Prochaska
Senior Associate Vice Provost, Clinical Research Governance and Professor of Medicine (Stanford Prevention Research Center)
Current Research and Scholarly InterestsDr. Prochaska's clinical trials research focuses on developing and testing evidence-based interventions for tobacco, other substance use, physical activity, and diet. She has led randomized controlled trials of treatments that combine motivational, behavioral, and pharmacologic strategies, including use of telemedicine, therapeutic relational agents, social-media–supported interventions, and tailored programs for socio-demographically diverse and at-risk groups to advance population health.
-
David Rehkopf
Professor of Epidemiology and Population Health, of Medicine (Primary Care and Population Health) and, by courtesy, of Pediatrics, of Health Policy and of Sociology
BioI am a social epidemiologist and serve as a Professor in the Department of Epidemiology and Population Health and in the Department of Medicine in the Division of Primary Care and Population Health. I joined the faculty at Stanford School of Medicine in 2011.
I am Director of the Stanford Center for Population Health Sciences. In this position, I am committed to making high-value data resources available to researchers across disciplines in order to better enable them to answer their most pressing clinical and population health questions.
My own research is focused on understanding the health implications of the myriad decisions that are made by corporations and governments every day - decisions that profoundly shape the social and economic worlds in which we live and work. While these changes are often invisible to us on a daily basis, these seemingly minor actions and decisions form structural nudges that can create better or worse health at a population level. My work demonstrates the health implications of corporate and governmental decisions that can give the public and policy makers evidence to support new strategies for promoting health and well-being. In all of his work, I have a focus on the implications of these exposures for health inequalities.
Since often policy and programmatic changes can take decades to influence health, my work also includes more basic research in understanding biological signals that may act as early warning signs of systemic disease, in particular accelerated aging. I examine how social and economic policy changes influence a range of early markers of disease and aging, with a particular recent focus on DNA methylation. I am supported by several grants from the National Institute on Aging and the National Institute on Minority Health and Health Disparities to develop new more sensitive ways to understand the health implications of social and economic policy changes. -
Thomas Robinson
The Irving Schulman, M.D. Professor of Child Health, Professor of Medicine (Stanford Prevention Research Center) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsDr. Robinson originated the solution-oriented research paradigm and directs the Stanford Solutions Science Lab. He is known for his pioneering obesity prevention and treatment research, including the concept of stealth interventions. His research applies social cognitive models of behavior change to behavioral, social, environmental and policy interventions for children and families in real world settings, making the results relevant for informing clinical and public health practice and policy.
-
Lisa Goldman Rosas
Associate Professor (Research) of Epidemiology and Population Health, of Medicine (Primary Care and Population Health) and, by courtesy, of Pediatrics
BioLisa Goldman Rosas, PhD MPH is an Associate Professor in the Department of Epidemiology and Population Health and the Department of Medicine, Division of Primary Care and Population Health at Stanford School of Medicine. An epidemiologist by training, Dr. Goldman Rosas’ research focuses on addressing disparities in diet-related chronic diseases such as diabetes, heart disease, depression, and cancer especially for those who face food insecurity. This research features rigorous quantitative and qualitative methodologies, participatory qualitative approaches, and shared leadership with patient and community partners. She is passionate about integrating patients, caregivers, community organizations, and other key stakeholders in the research process in order to affect the greatest improvements in health and well-being. As a reflection of this passion, Dr. Goldman Rosas serves as the Faculty Director for the School of Medicine Office of Community Engagement, Co-Director of Community-Engaged Research for the Office of Cancer Health Equity, and Director of the Outreach, Recruitment and Engagement Core for the Alzheimer's Disease Research Center. In these roles, she supports other faculty and patient and community partners to develop sustainable and meaningful partnerships to support transformative research. In addition to research, she teaches at the undergraduate and graduate levels and has a special focus on increasing capacity in community engagement methods.
-
Lidia Schapira
Professor of Medicine (Oncology)
BioDr. Schapira is a medical oncologist with clinical expertise in the treatment of breast cancer. As the inaugural Director of Stanford's Cancer Survivorship Program, she has developed a thriving research and clinical program focused on optimizing health outcomes for people living with and beyond cancer. Dr. Schapira is interested in training future generations of physician-scientists as well as the broader community of practicing physicians through the design of innovative educational programs. Dr. Schapira's advocacy for people with cancer led to her appointment as Editor-in-Chief of the American Society of Clinical Oncology's website for the public,Cancer.Net, a position she held from 2015 until-2021. She served on the Board of Directors of the American Psychosocial Oncology Society and as Chair of the Psychosocial Interest Group of the Multinational Society for Supportive Care in Cancer. Dr. Schapira is particularily committed to reducing inequities in cancer outcomes and improve access to cancer care and cancer clinical trials. Dr. Schapira has published numerous manuscripts, lectures both nationally and internationally on issues of cancer survivorship and served as Associate Editor of the narrative section, Art of Oncology, for the Journal of Clinical Oncology from 2013 until 2023.
-
Nigam H. Shah, MBBS, PhD
Professor of Medicine (Biomedical Informatics), of Biomedical Data Science and, by courtesy, of Computer Science
Current Research and Scholarly InterestsWe answer clinical questions using aggregate patient data at the bedside. The Informatics Consult Service (https://greenbutton.stanford.edu/) put this idea in action and led to the creation of Atropos Health. We build predictive models that allow taking mitigating actions, keeping the human in the loop.
-
Stephanie Melissa Smith
Assistant Professor of Pediatrics (Hematology/Oncology)
Current Research and Scholarly InterestsI am involved with clinical research related to cancer survivorship, with a particular focus on late effects of childhood cancer treatments and community partnerships to improve health equity for adolescent/young adult cancer survivors in under-resourced settings.
